Author

Jacques Genest

Professor of Medicine - Cited by 26,506 - Cardiology

Biography

Jacques Genest obtained his MD at McGill University and did a residency in Internal Medicine at McGill then a cardiology fellowship at Tufts University in Boston. He did Post-doctoral studies in Boston in lipoprotein metabolism and molecular genetics at Tufts University. Since 2000, he is Professor of Medicine and holds the McGill/Novartis Chair in Medicine at McGill. From 2000-10, he was Head of Cardiology at McGill University. He was Director of the Center for Innovative Medicine at the McGill University Health Center (MUHC), 2010-14.
Title
Cited by
Year
Antiinflammatory therapy with canakinumab for atherosclerotic disease
PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, ...New England journal of medicine 377 (12), 1119-1131, 2017201
6767
2017
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo …
PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ...The Lancet 390 (10105), 1833-1842, 2017201
1030
2017
2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult
TJ Anderson, J Grégoire, GJ Pearson, AR Barry, P Couture, M Dawes, ...Canadian Journal of Cardiology 32 (11), 1263-1282, 2016201
952
2016
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled …
PM Ridker, JG MacFadyen, BM Everett, P Libby, T Thuren, RJ Glynn, ...The Lancet 391 (10118), 319-328, 2018201
714
2018
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe …
RD Santos, SS Gidding, RA Hegele, MA Cuchel, PJ Barter, GF Watts, ...The lancet Diabetes & endocrinology 4 (10), 850-861, 2016201
333
2016
2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults
GJ Pearson, G Thanassoulis, TJ Anderson, AR Barry, P Couture, N Dayan, ...Canadian journal of cardiology 37 (8), 1129-1150, 2021202
289
2021
Residual macrovascular risk in 2013: what have we learned?
JC Fruchart, J Davignon, MP Hermans, K Al-Rubeaan, P Amarenco, ...Cardiovascular Diabetology 13 (1), 1-17, 2014201
226
2014
High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk
A Hafiane, J GenestBBA clinical 3, 175-188, 2015201
223
2015
Overview of the current status of familial hypercholesterolaemia care in over 60 countries-The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
AJ Vallejo-Vaz, M De Marco, CAT Stevens, A Akram, T Freiberger, ...Atherosclerosis 277, 234-255, 2018201
172
2018
Canadian Cardiovascular Society position statement on familial hypercholesterolemia
J Genest, RA Hegele, J Bergeron, J Brophy, A Carpentier, P Couture, ...Canadian Journal of Cardiology 30 (12), 1471-1481, 2014201
110
2014
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ...The Lancet 398 (10312), 1713-1725, 2021202
105
2021
Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018
LR Brunham, I Ruel, S Aljenedil, JB Rivière, A Baass, JV Tu, GBJ Mancini, ...Canadian Journal of Cardiology 34 (12), 1553-1563, 2018201
104
2018
International atherosclerosis society severe familial hypercholesterolemia panel. Defining severe familial hypercholesterolaemia and the implications for clinical management: A …
RD Santos, SS Gidding, RA Hegele, MA Cuchel, PJ Barter, GF Watts, ...Lancet Diabetes Endocrinol 4 (10), 0-61, 2016201
85
2016
Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies
PP Toth, O Descamps, J Genest, N Sattar, D Preiss, R Dent, C Djedjos, ...Circulation 135 (19), 1819-1831, 2017201
70
2017
High-density lipoproteins: biology, epidemiology, and clinical management
HY Choi, A Hafiane, A Schwertani, J GenestCanadian Journal of Cardiology 33 (3), 325-333, 2017201
65
2017
Inflammation modulation and cardiovascular disease prevention
Z Awan, J GenestEuropean Journal of Preventive Cardiology 22 (6), 719-733, 2015201
61
2015
Simplified Canadian definition for familial hypercholesterolemia
I Ruel, D Brisson, S Aljenedil, Z Awan, A Baass, A Bélanger, J Bergeron, ...Canadian Journal of Cardiology 34 (9), 1210-1214, 2018201
59
2018
Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro
A Hafiane, JK Bielicki, JO Johansson, J GenestPloS one 10 (7), e0131997, 2015201
59
2015
HDL cholesterol and ASCVD risk stratification: a debate
P Barter, J GenestAtherosclerosis 283, 7-12, 2019201
54
2019
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study
TR Tromp, ML Hartgers, GK Hovingh, AJ Vallejo-Vaz, KK Ray, H Soran, ...The Lancet 399 (10326), 719-728, 2022202
54
2022

Referred From: https://scholar.google.com/citations?user=wh86FYkAAAAJ&hl=en

Cited by
Citations 26506
h-index 45
i10-index 70
Open Access Journals